Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (2018 - 2025)

X4 Pharmaceuticals' Shares Outstanding history spans 8 years, with the latest figure at $90.9 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 1495.35% year-over-year to $90.9 million; the TTM value through Dec 2025 reached $90.9 million, up 1495.35%, while the annual FY2025 figure was $90.9 million, 1495.35% up from the prior year.
  • Shares Outstanding reached $90.9 million in Q4 2025 per XFOR's latest filing, up from $25.1 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $164.7 million in Q3 2023 to a low of $4.1 million in Q4 2022.
  • Average Shares Outstanding over 5 years is $42.2 million, with a median of $24.6 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding: plummeted 96.59% in 2024, then skyrocketed 1495.35% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $28.1 million in 2021, then plummeted by 85.58% to $4.1 million in 2022, then skyrocketed by 37.62% to $5.6 million in 2023, then grew by 2.1% to $5.7 million in 2024, then surged by 1495.35% to $90.9 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Shares Outstanding are $90.9 million (Q4 2025), $25.1 million (Q3 2025), and $8.0 million (Q2 2025).